PD15-11 TRANSLOCATION RCC: PROGRESSION-FREE AND OVERALL SURVIVAL BY TUMOR STAGE AND SURGICAL PROCEDURE AT A HIGH-VOLUME ACADEMIC CENTER

You have accessJournal of UrologyCME1 May 2022PD15-11 TRANSLOCATION RCC: PROGRESSION-FREE AND OVERALL SURVIVAL BY TUMOR STAGE AND SURGICAL PROCEDURE AT A HIGH-VOLUME ACADEMIC CENTER Jason Farrow, Nate Hollowell, Connor Drake, Leo Song, Clint Cary, Clinton Bahler, Ronald Boris, and Chandru Sundaram Jason FarrowJason Farrow More articles by this author , Nate HollowellNate Hollowell More articles by this author , Connor DrakeConnor Drake More articles by this author , Leo SongLeo Song More articles by this author , Clint CaryClint Cary More articles by this author , Clinton BahlerClinton Bahler More articles by this author , Ronald BorisRonald Boris More articles by this author , and Chandru SundaramChandru Sundaram More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002547.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Translocation Renal Cell Carcinoma (RCC) is a rare variant and is estimated to represent 2-5% of RCC diagnoses. Prior studies characterizing the clinical behavior of translocation RCC are limited and stage-by-stage prognostication for adult patients remains uncertain. METHODS: Patients diagnosed with localized translocation RCC that underwent either partial or radical nephrectomy between 2004 and 2021 were reviewed. Standard clinico-pathologic characteristics were included. Both progression-free and overall survival were estimated using Kaplan Meier curves. Non-parametric tests in SAS were used with statistical significance set at 0.05. RESULTS: A total of 59 patients were identified. Age at surgery and Body Mass Index were balanced across pathological stage. Tumor complexity increased with stage, as did adverse pathological features (Fuhrman Grade 3-4, lymphovascular invasion, and margin positivity). Both progression-free and overall survival was worse for higher stage disease. Of note, low stage disease had favorable long-term survival approaching 90%; there was no difference in overall survival between partial or radical nephrectomy for low-stage disease. CONCLUSIONS: Translocation tumors predictably demonstrate worse pathological features with stage progression. Interestingly, those patients with low-stage disease had durable treatment responses with either partial or radical nephrectomy, suggesting minimally invasive approaches may be preferred to limit perioperative morbidity without sacrificing oncologic outcomes. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e267 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jason Farrow More articles by this author Nate Hollowell More articles by this author Connor Drake More articles by this author Leo Song More articles by this author Clint Cary More articles by this author Clinton Bahler More articles by this author Ronald Boris More articles by this author Chandru Sundaram More articles by this author Expand All Advertisement PDF DownloadLoading ...